Novartis Phase 3 RemIND Trial Meets Endpoints, $1.7B Unnatural Products Deal
Novartis' Phase 3 RemIND trial of oral remibrutinib in CIndU met primary endpoints across dermographism, cold and cholinergic urticaria at Week 12, showing significantly higher response rates versus placebo. Separately, Novartis inked a licensing deal worth up to $1.7 billion with Unnatural Products for a macrocyclic peptide cardiovascular program.
1. Positive Phase 3 RemIND Trial Results
Novartis released topline data from its pivotal Phase 3 RemIND trial of oral remibrutinib in chronic inducible urticaria (CIndU), meeting the primary endpoint across symptomatic dermographism, cold urticaria and cholinergic urticaria at Week 12 with significantly higher response rates versus placebo. These results underpin a supplemental New Drug Application to the FDA for symptomatic dermographism and position remibrutinib as the first targeted therapy for CIndU.
2. Macrocyclic Peptide Licensing Deal
Novartis signed a licensing agreement with Unnatural Products for development of macrocyclic peptide-based therapies in a cardiovascular program, with potential payments up to $1.7 billion. The deal grants Novartis exclusive rights to Unnatural Products’ macrocyclic peptide platform for undisclosed cardiovascular targets and includes research funding, development milestones and royalties.